Ahnefeld F W, Bässler K H, Grünert A, Halmágyi M, Mehnert H, Schmitz J E
Infusionsther Klin Ernahr. 1987 Jun;14(3):124-8.
The following types of carbohydrate intolerance are discussed as a risk in infusion therapy: Hereditary fructose intolerance, fructose-1,6-biphosphatase deficiency, impairment of glucose utilization during the post-aggression syndrome and/or in latent or overt diabetes mellitus. Asking about symptoms of fructose intolerance has to be part of every routine anamnesis. Application of any kind of carbohydrate requires differential therapeutic considerations. Undiscovered fructose intolerance is more likely the younger the patient is, whereas the frequency of glucose intolerance increases with age. In unconscious patients without anamnesis, fructose or sorbitol should not be applied. Never should an attempt be made to compensate falling blood glucose levels under infusion therapy by application of fructose or sorbitol. As carbohydrate addition to routine fluid and electrolyte substitution xylitol in the specified low dosage is without risk in a diabetes-like metabolic condition as well as in fructose intolerance.
遗传性果糖不耐受、果糖-1,6-二磷酸酶缺乏症、攻击后综合征期间及/或潜伏性或显性糖尿病中葡萄糖利用受损。询问果糖不耐受症状应成为每次常规问诊的一部分。使用任何种类的碳水化合物都需要进行差异化的治疗考量。患者年龄越小，未被发现的果糖不耐受可能性越大，而葡萄糖不耐受的发生率则随年龄增长而增加。对于无既往病史的昏迷患者，不应使用果糖或山梨醇。绝不应试图通过使用果糖或山梨醇来纠正输液治疗期间下降的血糖水平。作为常规液体和电解质补充剂中的碳水化合物添加物，特定低剂量的木糖醇在类似糖尿病的代谢状况以及果糖不耐受情况下均无风险。
